Utilization of HCV-Viremic Organs for HCV Negative Recipients: Is Practice Speeding Past the Evidence?
Over nearly 3 decades, organs from donors with hepatitis C virus (HCV) have been widely used for recipients with HCV without detrimental impact on recurrence, graft survival, or the incidence of cholestatic hepatitis. The recent availability of highly effective antiviral therapy has dramatically decreased the number of HCV-viremic transplant candidates, contributing to underutilization of HCV-viremic donors in recent years. Combined with an increase in HCV-viremic donors due to opioid overdose death, experts have proposed the use of HCV-viremic donors in HCV-negative transplant recipients with post-transplant DAA therapy.